FDA restricts leucovorin approval for autism treatment
The US Food and Drug Administration (FDA) announced a narrower approval for leucovorin, previously promoted by the Trump administration as a treatment for autism in children. Instead of expanding access to the medication for a broader population, the FDA has limited its use to individuals suffering from a rare genetic disorder, reports BritPanorama.
Parents and guardians of autistic children have expressed feelings of betrayal and confusion following the FDA’s announcement. Keith Joyce, a guardian for a 5-year-old son with autism who has taken leucovorin, stated, “I bet some probably feel betrayed. I kind of do.” He added that he felt validated in initially using the drug but now worries about the implications of the FDA’s retraction.
The FDA justified its decision by asserting a lack of “sufficient data” supporting leucovorin’s efficacy as a treatment for autism, with senior officials noting that its approval is now confined to cases of cerebral folate deficiency, a rare condition affecting fewer than 50 individuals worldwide. “It’ll be up to patients to talk with their physicians to just see if [leucovorin] might be right for them,” one official remarked.
Clinical experts, while agreeing that the FDA’s decision is not controversial, acknowledged the disappointment felt by parents. Andy Shih from Autism Speaks noted that the decision reflects the limited evidence supporting leucovorin’s effectiveness for autism. He reiterated the importance of relying on scientific data over anecdotal reports from families.
Interest in leucovorin had surged after the White House’s initial endorsement, prompting a marked increase in prescriptions, despite recommendations from professional associations against its use for autism. A recent report highlighted that leucovorin prescriptions rose significantly in late 2025, even amidst skepticism from the medical community regarding the drug’s applicability for autism treatment.
Future outlook for leucovorin and patient support
As the FDA’s shift in stance continues to resonate, uncertainty looms over whether healthcare providers will remain willing to prescribe leucovorin to their patients. Those advocating for the drug fear that the FDA’s recent findings might deter physicians from recommending it, despite ongoing demand from families. Giorgino Sawant, CEO of ReligenDX, noted a spike in inquiries related to the drug following the FDA’s announcement, suggesting that the interest in leucovorin remains substantial.
Healthcare professionals urge caution, especially given the high doses of leucovorin prescribed to children. Dr. Audrey Brumback cautioned parents to work with specialists, as dosage levels significantly exceed typical daily requirements of folate, the drug’s active ingredient. She emphasized that potential improvements noticed by parents may not correspond directly to the drug’s effects but could reflect normal developmental progress.
The ongoing conversation surrounding leucovorin underscores the complex landscape of autism treatment. Families are encouraged to pursue comprehensive care plans tailored to their children’s needs, involving genetic testing and behavioral therapies as viable options for enhancing quality of life.
As debates surrounding leucovorin’s role in autism treatment continue, the need for thorough communication between healthcare providers and families remains paramount.
